Entero Healthcare Solutions Limited delivered robust top-line and bottom-line growth in Q1FY27, with consolidated revenue rising 38.2% year-on-year to ₹1,940 crore. The company achieved an EBITDA margin of 5% in the quarter, matching its full-year FY27 guidance ahead of schedule. Profit after tax (PAT) surged 72% to ₹52 crore, driven by significant margin expansion and operational efficiencies.

Financial Performance

The revenue growth was supported by both organic and inorganic factors. Organic revenue grew 17.8% on a reported basis and 19.6% on a like-for-like basis, outpacing the underlying pharmaceutical market growth of 13.8%. Inorganic growth contributed 20.4%, primarily from the calendarization of acquisitions completed in the previous fiscal year. No new acquisitions were made during Q1FY27.

EBITDA grew 94% year-on-year, nearly 2.5 times the revenue growth rate. This disproportionate expansion was attributed to scale-led procurement economies, a higher share of revenue from the MedTech business, and the deliberate exit from low-margin accounts. The exit of low-margin businesses impacted reported growth by approximately 2.5% but released working capital for deployment in higher-return opportunities.

What the Numbers Show

A key analytical observation is the divergence between total PAT growth and PAT attributable to owners. While total PAT rose 72% to ₹52 crore, PAT attributable to owners increased by 37% to ₹38 crore. This gap is due to non-controlling interest, which stood at ₹14 crore (approximately 27% of profit before minority interest). Management clarified that this reflects the performance of majority-owned subsidiaries where residual minority stakes are held under pre-agreed call options, rather than value leakage. The minority share of profit is reinvested in the business, and the company retains full operational control.

Operational Highlights & Guidance

Return ratios showed marked improvement, with Return on Capital Employed (ROCE) doubling from 11.5% to 21.1% and Return on Equity (ROE) rising from 9% to 20.4%. Net working capital days improved to 61 days from 66 days a year ago, indicating continued structural efficiency gains.

The MedTech segment remains a critical margin lever, with revenue on track to cross ₹1,000 crore organically in FY27. This segment carries higher gross and EBITDA margins compared to the core pharmaceutical distribution business. Operationally, Entero now serves over 72,000 retail customers and 2,300 hospital customers, distributing over 83,400 SKUs across 138 warehouses in 19 states.

Management reaffirmed its FY27 guidance of approximately 23% consolidated revenue growth (excluding new acquisitions) and a 5% EBITDA margin. The company also maintained its target of converting 50% of EBITDA to operating cash flow. For the medium term, management expects organic growth to exceed 20% annually, leveraging its pan-India network and two-way moat between suppliers and customers.

Entero Healthcare Solutions reported a consolidated net profit of ₹520.51 million for the quarter ended June 30, 2026, marking an 89% year-on-year increase from ₹302.32 million in the corresponding period of FY26. The Mumbai-based pharmaceutical distributor saw consolidated revenue from operations rise 38% to ₹19,404.95 million, driven primarily by the inclusion of new subsidiaries acquired during FY26. This top-line expansion significantly boosted group earnings, although standalone performance diverged sharply with net profit halving to ₹34.57 million as higher finance costs offset modest revenue growth at the holding level.

The Board of Directors approved the unaudited financial results on August 7, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors M S K A & Associates LLP issued limited review reports with unmodified opinions for both standalone and consolidated statements. In compliance with Regulation 47 of the SEBI (LODR) Regulations, 2015, the company published extracts of the results in 'Financial Express' and 'Satyajay Times' on August 8, 2026. The trading window for securities opened after the expiry of 48 hours from the disclosure of results.

Financial Performance

Consolidated earnings per share (EPS) rose to ₹8.77 from ₹6.39 in Q1FY26. Profit attributable to owners of the company increased 37% to ₹381.62 million. Standalone EPS fell to ₹0.79 from ₹1.60, reflecting a decline in standalone profit before tax to ₹46.05 million from ₹91.64 million. On the operational front, consolidated EBITDA nearly doubled to ₹969 million from ₹502 million year-on-year, with EBITDA margin expanding to 4.99% from 3.52%, reflecting improved operating leverage across the group's expanded subsidiary base.

The following table summarises the key financial metrics for the quarter:

Corporate Actions and Committee Reconstitution

The Board reconstituted its Audit, Nomination and Remuneration, and Stakeholders Relationship Committees effective August 25, 2026, following the completion of Rajesh Shashikant Dalal's tenure as Non-Executive Independent Director. Sandhya Gadkari Sharma chairs both the Audit and Nomination committees. Sujesh Vasudevan now chairs the Stakeholders Relationship Committee.

During the quarter, the holding company subscribed to Optionally Convertible Debentures (OCDs) issued by four subsidiaries: Saurashtra Medisolutions Private Limited, Sri Parshva Pharma Distributors Private Limited, S.S. Pharma Traders Private Limited, and Avenues Pharma Distributors Private Limited. The company also allotted 12,135 equity shares at a premium of ₹794 per share, aggregating to ₹9.76 million, pursuant to employee stock option exercises. Additionally, 24,800 ESOPs were granted under the Entero Employee Stock Option Plan 2023.

What the Numbers Show

A significant divergence exists between consolidated and standalone profitability drivers. While consolidated revenue surged 38% YoY, standalone revenue grew only 5%. More critically, standalone other income dropped 12% to ₹231.45 million from ₹262.88 million, and finance costs nearly decapentupled to ₹57.42 million from ₹5.94 million. This suggests that the holding company is bearing disproportionate financing costs relative to its operational scale, whereas subsidiaries are generating the bulk of the group's operational leverage. The consolidation of seven new entities during FY26—such as Ramson Medical Distributors and Anand Chemiceutics—explains the top-line expansion but also introduces integration complexity, evidenced by the non-comparability of certain quarterly figures.